Immunome (IMNM) Equity Average (2019 - 2026)

Immunome has reported Equity Average for 8 years, with the latest figure at $611.5 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 150.47% year-over-year to $611.5 million; the trailing twelve-month figure through Mar 2026 stood at $611.5 million (up 150.47% YoY), and the FY2025 full-year result was $407.8 million, up 170.89% from the prior year.
• Equity Average for Q1 2026 stood at $611.5 million, up from $449.1 million in the prior quarter.
• The five-year high for Equity Average was $611.5 million in Q1 2026, with the low at $7.7 million in Q3 2023.
• Historically, Equity Average has averaged $175.6 million across 5 years, with a median of $198.0 million in 2024.
• Annual changes were most pronounced in 2023 — Equity Average sank 71.11% — and 2024, when it jumped 2941.03%.
• Immunome's Equity Average stood at $19.9 million in 2022, then surged by 216.98% to $63.0 million in 2023, then soared by 214.45% to $198.0 million in 2024, then jumped by 126.79% to $449.1 million in 2025, then surged by 36.16% to $611.5 million in 2026.
• The last three Equity Average figures came in at $611.5 million (Q1 2026), $449.1 million (Q4 2025), and $266.6 million (Q3 2025), per Business Quant data.